Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Minia University
- Target Recruit Count
- 45
- Registration Number
- NCT05653245
- Locations
- 🇪🇬
Shaimaa Hamdy, Minya, Egypt
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Conditions
- Metastatic Prostate CancerNon-metastatic Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Praful Ravi, MB BCHir, MRCP
- Target Recruit Count
- 9
- Registration Number
- NCT05617885
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
Tranquility Research, Webster, Texas, United States
🇺🇸Bon Secours Cancer Institute, Midlothian, Virginia, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Conditions
- HER2-negative Breast CancerAdvanced Breast CancerBreast NeoplasmBreast CancerHormone Receptor Positive Tumor
- Interventions
- Drug: AKT inhibitorDrug: CarrelizumabDrug: SHR-1167Drug: TPCDrug: SHR-6209
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Breast NeoplasmHER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorBreast CancerBreast TumorsHormone Receptor Negative TumorTriple-Negative Breast Cancer (TNBC)Locally Advanced Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
- Conditions
- Pancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- European Institute of Oncology
- Target Recruit Count
- 11
- Registration Number
- NCT05568017
- Locations
- 🇮🇹
Chiara Maria Grana, Milano, Italy
Phase II Dutasteride in Combination With CAB vs CAB in SDC
- Conditions
- Salivary Duct Carcinoma
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT05513365
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Gelderland, Netherlands
Study of PAT in Patients With Solid Tumor Cancers
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 21
- Registration Number
- NCT05338658
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: Local treatment for primary lesionRadiation: Radiotherapy for primary lesionRadiation: Radiotherapy for metastatic lesion
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT05212857
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy of Different Agents in Treatment of Initial Caries on Smooth Surfaces in Permanent Teeth in Children
- Conditions
- White Spot Lesion of Tooth
- Interventions
- Other: Control Group, No Treatment
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Plovdiv Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT05206539
- Locations
- 🇧🇬
Department of Pediatric Dentistry, Faculty of Dental Medicine, Medical University - Plovdiv, Plovdiv, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.